Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a clinical-stage biotechnology company founded in 2011 and headquartered in Victoria, Canada. Originally incorporated as Plaza Capital Partners Inc., the company changed its name to Eupraxia Pharmaceuticals in May 2012. The company focuses on developing innovative drug delivery technologies for treating inflammatory conditions and pain management, with its lead programs currently in Phase II and Phase III clinical trials.
Latest newsMore news →
Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis patients, showing reductions in odynophagia and dysphagia severity through 52 weeks post treatment.38d agoEupraxia Pharmaceuticals presented new data at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI.40d agoEupraxia Pharmaceuticals appointed Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its Board of Directors.75d ago